INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 433m ago
HOUSE PTR32m ago
SEC 13F32m ago
ROBINHOOD CHAIN32m ago
SEC FORM 4/Grant or awardVerified data

Ackles Robert William reported ADRX

Chief People Officer · ADARx Pharmaceuticals, Inc. · ADARx Pharmaceuticals, Inc. — Employee Stock Option (right to buy)

Side
A
Value
—
Shares
85.3K
Price
—
Executed
Sep 24, 2026
Disclosed
Sep 28, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Sep 24 executedSep 28, 2026 disclosed

ADRX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

    No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ADRX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    LZ
    Li ZhenDirector, President and CEO, 10% Owner
    ADRXADARx Pharmaceuticals, Inc.
    Grant or award
    		A—
    1.02M sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    9
    MR
    MacLeod Alan RobertChief Scientific Officer
    ADRXADARx Pharmaceuticals, Inc.
    Grant or award
    		A—
    170.7K sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    9
    ZN
    Zhu Rui (NMN)Chief Technology Officer
    ADRXADARx Pharmaceuticals, Inc.
    Grant or award
    		A—
    512.1K sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    9
    FR
    Fisk RyanCFO and CBO
    ADRXADARx Pharmaceuticals, Inc.
    Grant or award
    		A—
    170.7K sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002153534-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 24, 2026
    Published
    Sep 28, 2026
    Ingested by INSIDER
    Nov 5, 02:14 UTC
    Last re-read
    Nov 5, 02:14 UTC

    Extracted facts

    Filer
    Ackles Robert William
    Role
    Chief People Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    ADARx Pharmaceuticals, Inc. — Employee Stock Option (right to buy)
    Ticker
    ADRX
    Shares
    85.3K
    Price per share
    $0
    Execution date (reported)
    Sep 24, 2026
    Owned after transaction
    85.3K shares
    Days from execution to publication
    4

    What this establishes

    Ackles Robert William filed this Form 4 reporting a grant or award of ADRX on Sep 24, 2026. It became public on Sep 28, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief People Officer
    Ackles Robert Williamcik:0002153534
    Issuer
    ADARx Pharmaceuticals, Inc.cik:0001802369

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.